62 - Documentation, Informed Consent, and Safety Reporting (S23E3)

Okay, so today, we're going deep on something
that's super important, even though it might
not sound super exciting right off the bat. Yeah,
documentation, informed consent, and safety reporting
in clinical trials, you know, all that good stuff.
It might seem kind of dry at first glance, but
honestly, understanding this stuff is like...
understanding how we know that the medicines
we take are actually safe and work like they
should. It's like the foundation of trust in
the whole process. Exactly. So for this deep
dive, we've gone through a ton of material. I
mean, we're talking Regulation Street from CFR
Title 21. Oh, yeah. That one covers a lot of
ground. It does. It does. From the actual making
of the drugs to how the clinical trials are run.
And of course, we've got those ICH guidelines.
International ones, right? Yep. Plus, we dove
into those detailed GMP handbooks. GMP. So good
manufacturing practices. That's always key. Absolutely.
We even looked at how quality audits actually
work. Those manuals are fascinating. And to get
a real feel for things, we checked out some YouTube
videos, too. You know, workshops and talks from
FDA folks and experts in the industry. Yeah,
that's where you get those real -world insights.
Exactly. And just to round things out, we even
looked back at some historical stuff, like the
whole thalidomide tragedy. Oh, man. That one
really shows why we need these processes in place.
It does. It's a stark reminder. For sure. So
what we're aiming for today is to sort of distill
all this information, all these different sources,
into something clear and understandable. Yeah.
through the noise. Exactly. We want to make the
key parts of documentation, informed consent,
and safety reporting clear and, dare I say, engaging.
Well, we can try at least. We can try. So think
of this as like your cheat sheet to these really
important parts of clinical trials. Your shortcut
to the essentials. Right. So let's jump right
in. And I think the natural place to start is
with documentation. Absolutely. It's a foundation.
It is. And there's that one phrase that keeps
popping up everywhere we looked, especially in
those GMP materials. Oh, you mean if it's not
documented, it didn't happen? That's the one.
It's so simple, but so powerful. It really is,
especially when you think about how regulated
this whole field is. Right. So why is that phrase
so crucial? What makes documentation so important
in the grand scheme of things? Well, think about
it. Documentation is like the proof. It's the
evidence that everything was done right, that
every step was followed, every observation recorded,
every decision made, all the way from the beginning
of a trial to developing the actual product.
It's like the paper trail that shows everything
was done by the book. Exactly. And without it,
you can't really prove that the study was done
correctly, that the data is accurate, that the
equipment was working right. And if you can't
prove it, you can't really trust the results,
right? Exactly. And that's a huge problem. It
can impact patient safety, and it just makes
the whole thing less credible. Makes sense. So
it's not just about writing down that something
happened, but also when it happened. Oh, absolutely.
That's what they call contemporaneous documentation.
The FDA folks in their YouTube videos on those
bioanalytical inspections really hammered that
home. And we saw that a lot in the GMP handbooks
too, right? All over the place. It's super important.
You need to be recording things in real time
as they're happening. Not trying to remember
later and write it down, right? Nope. That's
not good enough. And the level of detail matters,
too. You need enough information that someone
who wasn't there could understand what went down
and why. So time stamps for like sample collections,
the idea of the specific equipment used, that
kind of thing. All of that. And any time you
deviate from the plan and need changes to the
protocol, you've got to document the reason for
it. It's all about transparency. It really is.
Now, when it comes to actually writing things
down, those YouTube videos on good documentation
practices got really specific. Especially for
handwritten stuff. Oh, yeah black indelible ink
only No pencils allowed that was clear very clear
and they were really big on making sure everything's
legible Which makes sense if you can't read it.
What's the point? Exactly and no ditto marks
or empty spaces either those can cause confusion
or even worse Someone could tamper with the records
later on and if you need to make a correction
single line through it Originals got to stay
visible then your initials and the date of the
correction. It's all about that audit trail.
Yep. Got to be able to track everything. I remember
that Cheo's Lunch and Learn video. They had that
story about an investigator who got in trouble
just because they forgot to date their signature
on a document. Oh yeah, I remember that. It seems
like a small thing, but it shows how seriously
they take this stuff. It does. A small oversight
like that can be a red flag for an auditor. What
do you think goes through their mind when they
see something like that? I think it makes them
wonder if there's a bigger problem, like if they're
not paying attention to details like that, what
else are they missing? Right, it makes you question
their overall rigor and if they really understand
the regulations. Exactly, and it just undermines
confidence in the whole study. Now when it comes
to electronic records, it's the same principles,
but the implementation is totally different.
Yeah, the focus shifts to validating the systems
themselves. Making sure they're reliable and
do what they're supposed to. and that the audit
trails are rock solid. Those are super important.
What makes them so essential in an electronic
system? Well, think of it like a log that records
every single change made to a record, who made
it, when, and sometimes even why. So it's like
a history of every action in the system. Exactly.
And it's all time stamped and secure, so you
can't really mess with it without leaving a trace.
Makes it a lot harder to hide any mistakes or
do anything shady. For sure. And you need secure
access controls, too. Not just anyone should
be able to get in there and make changes. And
you always want people entering the original
data directly into the system. No copying from
other sources or anything like that. Right. We
saw that emphasized in those YouTube discussions
and even in some of those season two transcripts
on data management. It's all about ensuring the
data is accurate. and reliable. Another thing
that stood out was the need for log books for
all those calibration and maintenance activities.
Oh yeah, the EA's consulting group folks were
big on that. It's like you need a record to show
that all the equipment used in the trial was
working properly. Absolutely, got to have that
proof. You can be confident in the data. Right,
and if anything goes wrong during maintenance
or calibration, you need to document that too
and what you did to fix it. Everything needs
to be accounted for. It does. And then there's
the question of how long you need to keep all
this documentation. It's not just a short -term
thing. No, not at all. EAS Consulting Group mentioned
at least six years, sometimes longer. And sometimes
even longer if it's related to a serious adverse
event. Why so long? What's the reasoning behind
that? Well, you need to be able to track safety
signals over the long term. So if something comes
up years after a drug is approved, you can go
back and look at the original data. That makes
sense. And you need to be able to respond to
any regulatory inquiries or audits that might
come up down the line. So it's about accountability
and being able to prove you did things right.
Exactly. And it shows that you're committed to
patient safety and data integrity. Now let's
talk a bit about batch records. Those are covered
in 21 CFR Part 211, and they seem super detailed.
They are. They're like the instruction manual
for making each batch of a drug. So every single
batch is made the same way? Right. Consistency
is key here. You want to make sure every batch
meets the same quality standards. So those master
production and control records lay out everything,
right? Everything. All the ingredients, the exact
amounts, what equipment to use, the steps in
the process, even the expected yield. And that
level of detail is essential to make sure every
batch is the same, right? Absolutely. It's all
about guaranteeing quality and purity. We also
can't forget about how to handle complaints.
That easy global training video on YouTube really
stressed that. Oh yeah, that's a big one. They
said it's not just good practice to have written
SOPs for everything. SOPs, those are standard
operating procedures. Right. So you need those
SOPs for how you receive complaints, document
them, investigate them, and resolve them. And
you need records to prove you follow those SOPs
every step of the way. So documentation isn't
just about the good stuff. It's also about how
you handle the problems. Exactly. It's about
learning from mistakes and making sure they don't
happen again. It's all part of that quality culture.
It is. So documentation is super important, but
it's also crucial for making sure informed consent
is done. Ethically right now our sources didn't
really get into the step -by -step process of
getting informed consent Yeah But they did emphasize
the ethical principle behind it that people need
to understand what they're signing up for and
they have to agree to participate voluntarily
and Documentation plays a huge role in ensuring
that happens How so? Well, think about it. If
important information about a participant isn't
documented properly, like their medical history,
it raises questions about whether they should
have even been in the trial in the first place.
Yeah, that came up in that OSIS workshop video.
It did. And if you're missing key information
like that, it looks like you didn't properly
assess their eligibility or the potential risks
for them. So it undermines the whole idea of
informed consent. It does. It makes it seem like
you're not really being upfront with people.
So those missing documents aren't just a procedural
oversight. They have real ethical implications.
Absolutely. And 21 CFR 312 .56 makes it clear
that sponsors have to monitor investigators to
make sure they're following the rules. Which
includes making sure informed consent is done
right. Right. So they have to check that the
investigators are sticking to the signed agreements,
like the FDA form 1572. And that they're following
the investigational plan. Which includes getting
informed consent prior. So it all ties back to
documentation? It does. It's all connected. Okay,
so we've covered documentation and how it relates
to informed consent. Let's move on to another
key area, safety reporting. This is all about
keeping track of what happens during a trial
and making sure any problems are reported to
the right people. And the sponsor plays a big
role here, right? They do. They're responsible
for maintaining a safety database that includes
all the new safety information that comes up
during the trial. Like any adverse events that
occur. Exactly. They have to be on top of that.
And there are two main types of safety reports
they need to know about, right? Those 15 day
reports and the seven day reports. Yep. Those
are the big ones. And those different timelines
depend on how serious the adverse event is, right?
Exactly. So for the 15 day reports, those are
for serious and unexpected adverse events that
are thought to be related to the drug being studied.
And serious has a specific meaning in this context,
right? It does. It usually means something like
death, a life -threatening event, hospitalization,
disability, or a birth defect. And unexpected
means it's not something that was already known
to be a potential side effect of the drug. Right.
It's something new or something that's happening
more often than expected. And these reports have
to be submitted to the FDA within 15 days of
the sponsor finding out about the event. Yep.
And they usually use a form called FDA 3500A
for that. Or they can do it in a narrative format
if it's an event that happened outside the U
.S. Right. And those reports go to this specific
FDA division that's overseeing that particular
IND application. That's the Investigational New
Drug application, right? Yep. And they need to
include a form called 1571. as a cover sheet,
so the FDA knows where to send it. So it's all
very structured and organized. It is. They have
a whole system in place. And then for those really
critical events, there are the seven -day reports.
Those for the most serious situations. Like when
someone dies, or there's a life -threatening
event. Right. And it has to be unexpected and
related to the drug. So in those cases, the FDA
needs to be notified right away, within seven
days. Yep. And they usually do that by phone
or fax. just to get the word out quickly. Exactly.
And then they have to follow up with a full written
report within 15 days. So it's like a two -step
process for those urgent situations. It is. They
want to make sure they get the information as
soon as possible. And this whole safety monitoring
thing doesn't just end when a drug gets approved,
right? No, it continues even after the drug is
on the market. We talked about that in season
eight about the challenges the FDA faces. It's
a constant process. They're always looking for
new safety information. And the sponsor has to
keep the investigators updated on any safety
events, too. Oh, yeah. Definitely. Everyone involved
needs to know what's going on. So it's a shared
responsibility. It is. Everyone's got to do their
part to keep patients safe. And of course, the
FDA plays a big role in all of this. They're
the ones who make sure everyone's following the
rules. They're the enforcers. That's right. And
we learned in that FDA CITC 2024 video that they
often do inspections, especially for new drugs,
or if there are big changes to an existing drug.
Inspections are a regular part of the process.
So what actually happens during an FDA Well,
FDA investigators go to the places where the
clinical trials are being done, or to the sponsor's
facilities or to the manufacturing plants, and
they check everything. They really dig in. They
do. They look at all the documentation. They
watch how people are doing their jobs. They interview
the staff. They want to make sure everything's
being done according to the regulations. And
sometimes they issue a form, FDA 483, right?
Yep. That's their way of saying they found some
potential problems. But it's important to remember
that those are just observations, right? They're
not necessarily proof that a rule was broken.
That's a crucial point. It just means the investigator
thinks something might be wrong. But the company
still has to take it seriously, right? Oh, absolutely.
They need to respond quickly and thoroughly.
That video said they have 15 business days to
respond. Yep. And they need to say whether they
agree or disagree with each observation. And
if they agree that something needs to be fixed,
they have to come up with a plan. A Corrective
and Preventive Action Plan, or KPA. Right, so
they need to say how they're going to fix the
problem and how they're going to stop it from
happening again. And they need to give timelines
and say how they'll check if the fix worked.
And of course they need to provide any documents
that support their response. It's all about showing
the FDA that they're taking things seriously.
And if the FDA finds more serious problems, they
might issue an OAI classification. That stands
for Official Action Indicated. And that's a much
bigger deal, right? It is. It means the FDA is
really concerned and they might take further
action. Like issuing a warning letter, delaying
approval of a drug, or even taking legal action.
So yeah, it's not something you want to get.
Definitely not. They also talked about those
remote regulatory assessments or RRAs in that
video. Those are kind of like virtual inspections,
right? Yeah. They're a newer way of doing things.
The FDA can request documents and hold meetings
online instead of having to send someone out
to the site. So it's more efficient. It can be,
and allows them to check in more often. But it
doesn't totally replace on -site inspections.
No. Those are still necessary in some cases.
But it shows that the FDA is trying to keep up
with the times. Definitely. They're adapting
to new technologies. So when you look at all
of this, all the documentation, the informed
consent, the safety reporting, the regulatory
oversight, it all boils down to one thing. Quality.
Absolutely. It's all about making sure that the
drugs we take are safe and effective. And those
processes aren't just about checking boxes. They're
about creating a culture of quality. That's a
key point. It's got to be ingrained in everything
you do. And it all ties into risk management,
too, right? Yeah. ICHQ9 talks about identifying
and mitigating risks. So you're not just reacting
to problems. You're trying to prevent them in
the first place. Exactly. And that's where documentation
comes in. You need to understand your processes
so you can figure out where the risks are. And
you need to train people properly so they know
how to do things right. That's crucial. Everyone
needs to be on the same page. And then you need
to keep track of everything so you can see if
your efforts are working. And make adjustments
if they're not. It's all about continuous improvement.
It is. It's a never -ending process. So to sum
it all up, documentation, informed consent, and
safety reporting are the cornerstones of responsible
clinical trials. They might seem like boring
details, but they're what make the whole system
work. They're what protect patients and make
sure the drugs we take are safe and effective.
And they're the basis for trust in the entire
process. Trust in the research, trust in the
regulators, trust in the medicines themselves.
Without them, the whole thing falls apart. So
here's a final thought for you to ponder. Go
ahead. If these processes are so important in
clinical trials, what other areas of our lives
could benefit from this level of rigor? That's
a good question. Like what if we applied these
principles to other industries or even to our
personal lives? Interesting idea. Could we improve
quality and build more trust? Something to think
about. It is. So we encourage you to dig into
those source materials we talked about. learn
more, ask questions. There's a lot to discover.
There is. Thanks for joining us on this deep
dive. We'll see you next time. See you then.